Compare Northrop Grumman Corporation (NOC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Tango Therapeutics Inc. — how do they compare? Northrop Grumman Corporation trades at $497.28 (market cap $68.39B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Northrop Grumman Corporation is far larger — about 18.2× Tango Therapeutics Inc.'s market cap, and Northrop Grumman Corporation pays a 2.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and Tango Therapeutics Inc. for 0 Days on average.
| NOC | TNGX | |
|---|---|---|
Market Cap | $68.39B | $3.75B |
Volume | 823,323 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $768.02 | $32.90 |
52-Week Low | $473.46 | $7.50 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $82.37B | $2.77B |
Dividend Yield | 2.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $495.69, up 2.2% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for the last three quarters, with a net income margin of 10.48% and a P/E ratio of 15.3. Recent news highlights a $20 billion Navy fighter contract loss to Boeing, though the company maintains a record backlog and a dividend payout.
The outlook is mixed: analyst consensus is bullish with a $595.69 price target, but technical indicators and recent contract loss pose near-term risks. Long-term growth is supported by defense spending and key programs like the B-21 bomber, though competitive pressures and execution risks remain.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
